In another Phase I trial, ten HER2+ refractory/metastatic patients (osteosarcoma (5), rhabdomyosarcoma (3), Ewing sarcoma (1), and synovial sarcoma (1)) were enrolled and treated with HER2-CAR T cells and lymphodepletion with either fludarabine or in combination with cyclophosphamide. The gene discussed is ERBB2; the disease is synovial sarcoma.